Biblio
Convalescent plasma for patients with multiple myeloma and COVID-19; the European Myeloma Network consensus. Leukemia. 2023.
. Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation. Leuk Lymphoma. 2023:1-8.
Improved Survival of Patients with Primary Plasma Cell Leukemia with VRd or Daratumumab-based Quadruplets: A Multicenter Study by the Greek Myeloma Study Group. Am J Hematol. 2023.
Obesity and multiple myeloma: emerging mechanisms and perspectives. Semin Cancer Biol. 2023.
. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. Lancet Oncol. 2023;24(6):e255-e269.
Proteasome inhibition in combination with immunotherapies: State-of-the-Art in multiple myeloma. Blood Rev. 2023:101100.
Carfilzomib 56 mg/m twice-weekly in combination with dexamethasone and daratumumab (KdD) versus daratumumab in combination with bortezomib and dexamethasone (DVd): a matching-adjusted indirect treatment comparison. Leuk Lymphoma. 2022:1-10.
. Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients. Clin Lymphoma Myeloma Leuk. 2022.
FlowCT for the analysis of large immunophenotypic datasets and biomarker discovery in cancer immunology. Blood Adv. 2021.
Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22(3):e105-e118.
Effect of induction therapy with lenalidomide, doxorubicin, and dexamethasone on bone remodeling and angiogenesis in newly diagnosed multiple myeloma. Int J Cancer. 2019.
Multiple myeloma: Role of autologous transplantation. Cancer Treat Rev. 2019;82:101929.
. Hodgkin's lymphoma (relapsed or refractory): autologous stem cell therapy. BMJ Clin Evid. 2015;2015.
.